TALS - Talaris Therapeutics up 10% on restructuring plan to pursue strategic alternatives

• Talaris Therapeutics ( NASDAQ: TALS ) is up 10% in premarket trading after announcing a corporate restructuring and starting a review of strategic alternatives.
• The cell therapy company is discontinuing two trials examining FCR001 for durable tolerance in living donor kidney transplant recipients. However, a phase 2 trial of the candidate testing its ability to induce tolerance in scleroderma will continue.
• Talaris ( TALS ) is also cutting its workforce by one-third. Remaining employees will focus on the FCR001 trial and the company's chemistry, manufacturing, and controls ("CMC") capabilities.
• The company said strategic alternatives could include business combinations and/or divesting its cell therapy CMC capabilities.
• Seeking Alpha's Quant Rating views Talaris ( TALS ) as a hold.

For further details see: